best breed innov sustain market
growth initi buy
lead anim health compani global track record deliv
consist strong growth busi driven two megatrend pet
becom integr part famili grow world-wide demand anim
protein despit challeng cattl busi see innov
upcom launch key maintain compani above-market growth
initi buy
global megatrend central lt growth outlook scale
diversif deliv particip global market companion
anim rev livestock rev highli divers portfolio
product line across six major categori critic driver growth
companion anim live longer becom integr famili
demand anim protein continu increas within context grow middl
class global given dynam anim health market expect reach
abl grow excess industri compound-annual-growth-rate
set embark phase growth innov expand
address market innov vaccin non-med feed driven
co poultri busi continu major opportun remain
swine china move toward industri hog farm new drug canin
allerg itch apoquel cytopoint fuel companion anim growth recent year
co launch anoth potenti blockbust brand simparica trio two
new biolog pain manag product dog cat tap launch
final littl disclos pipelin invest hefti annual
rev innov life-cycle manag program
bear fruit come year think deliv high single-digit top-lin
growth vs market low double-digit earn growth via margin
appear posit growth balanc sheet
provid downsid support recent reduc visit veterinarian
think remain well posit grow even recess
financi crisi given owner will curtail discretionari
spend take care pet see proprietari consum pet survey link
global popul grow boost demand anim protein cattl demand
reduc recess pork poultri consumpt typic increas
healthi balanc sheet cash net debt lever manag like
continu return cash sharehold via dividend execut bolt-on acquisit
enhanc growth also remain share buy-back program
includ forecast pt base
ep estim could prove conserv new pet care launch
exceed expect cattl busi robust forecast
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
continu exceed anim health market growth
led robust sale key companion anim health
exceed
cattl segment post growth compound-annual-growth-rate go
addit share buyback acquisit
growth sale exceed
cattl segment headwind abat return low
end market growth
oper margin
addit share repurchas
earlier expect competit apoquel
product fail gain signific traction companion
anim segment sale reach
cattl segment headwind remain stronger
expect post annual declin
oper margin
zoeti global leader anim health
market grow compound-annual-growth-rate see compani
well-posit continu deliv above-market
return key busi companion anim
livestock even recessionari period
secular trend increas medicin pet
age grow global demand anim protein
products/dairi bolster outlook although growth
cattl busi could remain depress see
innov companion anim apoquel cytopoint
simparica trio biolog pain product continu
line growth moreov solid dividend on-going
upsid could come accret tuck-in acquisit
continu expand address market
steadi quarterli annual financi perform
potenti increas stock dividend
potenti resumpt share buy-back program
pleas see import disclosur inform page report
initi coverag zoeti buy rate price target
zoeti largest pure play anim health compani world revenu
base compani compet anim health market focus product
livestock approxim corpor revenu companion anim
importantli compani highli diversifi product speci therapeut area
geographi present zoeti largest product apoquel repres sale
top product repres revenu importantli life-cycle manag
lack payer influenc loss exclus key product franchis gener
competit histor result major revenu cliff
year histori zoeti develop strong relationship key custom
larg livestock produc veterinarians/pet owner key relationship
innov product compani becom clear industri leader rank
geographi speci product categori zoeti receiv
approxim fda approv anim health medicin moreov past
five year compani introduc new life-cycle manag
zoeti built strong track record profit revenu growth bolster
acquisit signific cash flow gener post separ
zoeti steadili grown revenu compound-annual-growth-rate organ constant currenc
excess histor market growth broader anim
health segment notabl growth achiev despit variou challeng
livestock busi recent year period drought african swine fever etc
exogen factor influenc livestock produc decis flock herd size
directli affect use zoeti product
exclud acquisit believ compani continu post mid/high-single-
digit revenu growth wors market driven continu expans key
companion anim blockbust brand introduct innov therapi
come year context environ heighten risk
recess worth rememb anim health compani still deliv growth
prior financi crisi induc recess albeit low singl digit growth
resili companion anim famili will curtail discretionari spend
take care pet continu growth demand protein fact zoeti
pleas see import disclosur inform page report
indic veterinarian clinic revenu histor come top
custom want best pet
sentiment/behavior align jefferi proprietari consum survey us dog
owner link specif survey respond indic health economi
factor decis around own dog nearli note
dog part famili approxim respond would cut
spend categori moreov half consum indic
would chang spend dog treat chang less expens dog food
recess becam unemploy accord survey
chart vast major respond consid dog part famili
livestock side busi consum typic shift consumpt animal-
base protein less expens meat beef pork chicken
global economi fall protract recess like offset reduc cattl
medicin vaccin increas util anim health product swine
zoeti unlock valu independ compani captur bp improv
oper margin sinc separ pfizer
health year recent retir succeed kristin peck formerli
zoeti execut vice presid presid us oper new ceo octob
sinc spin-off lead anim health compani steadili
grown driven robust macro trend sector includ steadi popul growth
growth middl class world-wide two factor contribut
increas demand protein dairi dispos household incom
allow greater invest care pet becom integr part
famili time zoeti becom increasingli profit independ compani
due new higher-margin innov anim healthcar brand signific sg leverag
pleas see import disclosur inform page report
compani commerci platform synergi captur key acquisit
zoeti achiev oper margin versu
compani set embark phase growth via addit innov
recent key companion anim growth driver apoquel cytopoint simparica
continu deliv strong growth year reach matur
zoeti assembl late-stag pipelin extend market
growth trend beyond end although zoeti typic discuss specif
program develop competit reason compani annual
budget target candid among approxim half
innov new therapi half increment life-cycle manag
importantli compani recent launch new lifecycle/lin extens product
simparica trio tripl combin parasiticid could simplifi improv
complianc treatment flea tick gi parasit heartworm
tripl combin parasiticid alreadi market europ trio first
attract us parasiticid market launch commenc zoeti
believ trio becom blockbust product could gener increment sale
vs simparica franchis year see
simparica trio section follow trio manag indic anoth
mab target nerve-growth factor ngf treatment chronic pain associ
osteoarthr rare safeti issu relat osteonecrosi human studi may
limit use ngf human candid could repres signific advanc
treat chronic pain dog cat speci live long enough
joint damag manifest base regulatori file manag
expect mab pain product reach market next year higher-valu innov
product help improv zoeti product mix margin profil
busi develop acquisit also cornerston zoeti growth
addit introduc new anim health medicin vaccin noteworthi line
extens product zoeti util busi develop acquisit bolster
compani growth see chart follow expans presenc fast-
grow diagnost area purchas abaxi zoeti follow
sever bolt-on acquisit refer veterinarian lab given abil
leverag commerci platform global potenti extract signific synergi
look zoeti continu deploy cash addit bolt-on acquisit
diagnost well potenti adjac anim health segment
pleas see import disclosur inform page report
chart histor acquisit zoeti sinc ipo
near term dampen zoeti financi outlook long term
zoeti recent provid updat financi impact
confer call manag outlook reflect current headwind well
implic loom recess date compani indic
major disrupt suppli chain abil sourc api key product
note typic month raw materi hand thirti manufactur
site remain open around world approxim compani employe
continu work on-sit support essenti oper manufactur distribut
logist technic servic support custom key function suitabl
work home
said base shelter place guidelin across us europ manag
indic reduct vet visit pet owner similar
happen china earli specif zoeti indic vet clinic volum
us perhap rang certain intern market
like result lower demand certain companion anim product particularli
parasiticid normal peak util period northern
hemispher importantli manag believ modestli dampen
initi uptak simparica trio expect increment revenu impact
vs previous beyond simparica manag indic
strong companion anim portfolio doesnt requir pet owner go vet
clinic rx purchas on-line comparison note certain
busi would requir vet visit would experi greater impact
 diagnost repres zoeti overal revenu longer term
pandem seem fuel recent increas us pet adopt accord
media report latest shortag dog cat folk foster adopt pet
quarantin la time april etc trend confirm jefferi
proprietari consum pet survey see chart could potenti acceler zoeti
financi perform come current crisi
pleas see import disclosur inform page report
chart one four respond indic got new pet past month
livestock side busi signific reduct travel fewer
peopl eat there less demand beef/steak restaurant-s portion tend
larger consum cook home major headwind point
reduc demand anim protein could dampen growth outlook key livestock
busi current pandem becom protract
headwind includ close border increas inventori protein product
stuck variou port slowli move suppli chain factor
could reduc futur product excess inventori consum longer
term unclear much impact futur protein demand
social activ begin normal affect countri end zoeti indic
demand pork china yet return prior level follow swine
fever last year although difficult teas impact swine fever versu tariff
result us-china trade disput
healthi balanc sheet offer downsid support addit could
deploy share buyback bolt-on acquisit
current cash net debt leverag ratio
zoeti strong balanc sheet execut compani growth strategi
alon zoeti return share repurchas dividend
sharehold moreov compani made intern extern invest total
last year capit expens
busi develop activ said follow recent increas quarterli
dividend anoth deploy share repurchas remain
manag temporarili suspend share buyback conserv cash
crisi nonetheless believ zoeti sharehold downsid support
dip near- term earn assum return normalci given strength
compani balanc sheet would also expect manag continu deliv
accret bolt-on enhanc zoeti growth profil
pleas see import disclosur inform page report
valu zoeti alway challeng part rel publicli
trade pure-play anim health compani use compar four top
animal-health-focus compani list us three top
subsidiari major pharmaceut compani part conglomer
compani list europ two privat held
howev given strong track record execut steadi predict growth zoeti
becom premier growth stock recent year garner valuat match
end zoeti consist met exceed expect sinc becom public
compani seven year ago public compani zoeti multipl gradual
expand time due steadi revenu earn growth well cash gener
deploy dividend share repurchas
past five year zoeti stock trade averag current-year consensu
earn estim recent juli februari prior impact
share trade averag current year consensu earn
estim believ recent multipl expans relat part grow
expect near-term earn acceler driven introduct new
innov companion anim product simparica trio mab pain product
basi zoeti share trade price-to-earnings growth averag past
five year recent juli februari
pleas see import disclosur inform page report
chart forward price-to-earnings multipl past year
chart ev/ebitda ev/sal multipl past year
cross-check also look potenti publicly-trad compar
although acknowledg limit number publicly-trad anim health compar
compani believ reason expand zoeti compar list includ
top-tier healthcar compani even consum product compani predict
revenu earn growth well sustain cash flow gener characterist
view best compar compani includ anim health/diagnost
beirsdorf este lauder loreal etc consum product alcon healthcare/med
devic current trade current year consensu price-to-earnings
project high single-digit low double-digit growth
pleas see import disclosur inform page report
chart potenti compar zoeti
within context zoeti recent price-to-earnings multipl juli februari
rang multipl compar compani cite think reason
investor could continu ascrib premium multipl zoeti
establish initi price target base ep estim
believ repres normal year earn follow impact
pandem recoveri expect earliest
valuat also support dcf analysi
look anoth way price object consist discount cash flow
analysi dcf see evalu zoeti fully-tax oper compani
forecast window use discount rate forecast
period termin valu calcul believ appropri reflect risk
profil zoeti given strong track record execut deliv sustain above-
market growth appli termin growth rate seem adequ captur
latent growth profil zoeti product portfolio strong secular demand anim
protein dairi livestock well innov companion anim product
said dcf assumpt could prove conserv anim health market
continu grow long run taken togeth analysi yield
pleas see import disclosur inform page report
enterpris valu adjust cash debt produc npv
equiti valu per share year
chart dcf valuat assum fulli tax oper model except per share data
pleas see import disclosur inform page report
develop regulatori risk zoeti oper regul environ product
develop risk lower human pharmaceut still risk
associ anim health potenti setback could put zoeti
competit disadvantag rel key competitor potenti restrict ban
use anim health product medicines/vaccin regulatori action rais
process consumpt food-produc anim could reduc demand zoeti
product includ potenti increas restrict use antibacteri
account nearli zoeti revenu certain geographi includ
us eu china etc implement use electron prescript
led disciplin use antibiot alreadi certain market
consum prefer protein produc without use antibiot emerg
off-set demand increas zoeti vaccin altern medicin feed without
food safeti zoonot diseas perceiv advers effect human health link
consumpt food deriv anim util zoeti product could emerg
diseas etc could neg affect sale product livestock
mankind expand anim habitat increas agricultur product
brazil china etc increas risk potenti transmiss diseas
wildlif human zoonot diseas exampl avian flu
peak led reduc chicken meat product china one third recent
african swine fever result loss chinese-produc hog nearli
quarter world suppli frequenc impact diseas livestock
difficult predict creat great fluctuat demand anim health
macro environ increas cost rais livestock advers weather
avail natur resourc fresh water graze pastur etc could advers affect
livestock product reduc demand zoeti product sign climat chang
caus prolong drought extrem temperatur chang advers weather condit
could increasingli creat challeng environ livestock product
neg affect demand compani product
new increas competit human pharmaceut develop zoeti may
face competit lower-pr gener altern margin price differenti
rel gener product may widen caus shift toward increas use gener
drug next sever year key patent draxxin tulathromycin februari
revolution/stronghold selamectin novemb exced cetiofur
repres zoeti revenu set expir new life-cycle
manag product prefer brand zoeti believ revenu
key product erod gradual rel human gener competit note
typic eros due gener competit anim health rang
several-year period versu typic revenu eros human brand within
month gener entri addit anim health competit market may
experi increas competit current product area develop
new product consolid anim healthcar market recent year creat
pleas see import disclosur inform page report
larger potenti better-en compani abl leverag broader product
portfolio competit zoeti veterinarian clinic
histor key zoeti success compani symbiot relationship
veterinarian recommend treatment companion anim often sell
product directli pet owner recent year chang distribut
channel companion anim product increas use store brand over-the-counter product
increas sale mail-ord channel mass retail etc could advers
affect zoeti market share distribut product support veterinarian partner
zoeti implement minimum advertis price map polici agreement
e-commerc retail ensur advertis zoeti product
beyond certain price help elimin gray market
compani drug provid pet owner conveni fill prescript
want
execut risk zoeti histor success execut state
busi strategi compani could experi misstep point time
includ failur acquir futur growth driver well inabl achiev expect
margin improv long time ceo juan ramn alaix recent retir lead
zoeti year new ceo kristin peck season zoeti veteran along
deep bench compani appear well posit continu drive market
geopolit foreign exchang risk chang us law agreement polici
govern foreign trade export could neg affect custom busi
advers affect zoeti oper result exampl recent us-chines trade
disput result tariff us pork go china could reduc
demand us pork produc creat neg headwind zoeti sale
produc moreov zoeti sourc activ pharmaceut ingredi api
raw materi global basi said increas tariff could result higher cost
manufactur neg affect zoeti oper margin compani
success navig recent export challeng prolong trade disput
could potenti emerg drag zoeti busi
zoeti histor manag foreign exchang risk princip translat exposur
euro brazilian real australian dollar part oper includ
manag same-curr revenu relat same-curr cost given potenti
signific currenc swing driven macroeconom develop zoeti may
abl fulli off-set currenc headwind oper could advers
affect compani earn compani revenu denomin
foreign currenc result unfavor impact zoeti us-dollar base
pleas see import disclosur inform page report
world
discoveri develop manufactur
commerci veterinari vaccin medicin zoeti form juli
busi previous wholly-own subsidiari
exist sinc compani approxim world-wide employe
approxim direct sale oper countri veterinari
 scientist compani headquart parsippani new jersey zoeti
signific campu kalamazoo mi numer satellit facil around
world inclus distribut partner zoeti product sold
countri around world prior separ zoeti anim health divis
product develop function independ sinc
sinc separ zoeti steadili grown revenu compound-annual-growth-rate
constant currenc increas adjust ebit oper
incom compound-annual-growth-rate post acquisit abaxi lead
global provid veterinari point-of-car diagnost instrument complet juli
zoeti revenu expect reach prior emerg
chart track record consist deliv above-market top-lin growth
importantli zoeti deriv revenu divers portfolio approxim
pain sedat oncolog antiemet allergy/dermatolog reproduct product
anti-infect parasiticid medic feed addit anim health diagnost
cover eight speci apoquel jak inhibitor treat atop dermat allerg
itch zoeti largest product fifth-year sale total
pleas see import disclosur inform page report
revenu compani top product repres revenu
remain corpor sale deriv product
chart zoeti divers durabl innov portfolio
zoeti blockbust product sale exceed fact
compani lead brand repres one-third blockbust product
anim health industri recent simparica oral parasiticid cytopoint
monoclon antibodi achiev design post annual sale
simparica cytopoint reach sale
zoeti oper regul environ anim health busi differ
number posit way human pharmaceut see section anim
busi anim health mani way similar over-the-counter pharmaceut
larger blockbust product size cash flow key franchis
sustain typic long past patent expiri innov introduc
new life-cycle manag product past five year
pleas see import disclosur inform page report
anim health busi
global popul growth grow middl class increas urban underpin
strong fundament anim health industri accord vetnosi lead
industri consult firm anim health steadili grow market
intersect two dynam sector companion animal/pet care livestock
market exclud livestock feed pet food pois reach
repres compound-annual-growth-rate propel two long-term secular driver increas
demand anim protein product companion anim live longer
becom integr famili specif vetnosi forecast dog
cat hors treat drive growth companion anim
segment livestock market us organ econom co-
oper develop oecd project increas protein consumpt
order meat ton milk ton
follow zoeti recent expans diagnost devic digit domain
compani target address market opportun
brand loyalti pay
given distribut sale anim health product histor high brand
loyalti busi market abl leverag relationship key custom
 larger livestock produc veterinari offic etc moreov anim health primarili
cash pay busi somewhat insul third-parti payer fact
busi perspect vet clinic incent recommend brand product
abl gener meaning margin practic henc tandem
smaller price differenti brand gener product typic much
less gener pressur greater sustain cash flow product franchis
henc cash flow perspect anim health mani way similar human over-the-counter
pleas see import disclosur inform page report
pharmaceut averag age zoeti top product franchis nearli
minim impact gener entrant
whole level gener competit vari market market typic
greater competit europ certain emerg market us unlik
human health market larg well-capit compani focus gener
anim health product exist global competitor given smaller averag size
product opportun direct distribut veterinarian livestock
produc discuss
exampl zoetis/pf launch rimadyl carprofen nsaid pain
manag achiev initi sale nearli zoeti subsequ introduc
two line-extens product brand inject chewabl formul
drove sale despit introduct gener
altern chewabl form start revenu pain manag
product declin year follow gener competit
anoth exampl zoeti terramycin anti-infect launch
generic still contribut close revenu
compani draxxin anti-infect line continu gener blockbust level revenu
year market despit emerg
gener competit colombia vietnam russia poland croatia manag
believ similar scenario manag revenu declin could play draxxin
addit gener altern reach us market
anim vs human pharma drug lower risk lower quicker
anim health regul industri creat challeng oversight product
approv food safeti etc particip convers regul also creat barrier
entri lead optim environ minim competit
rel human pharmaceut actual number factor make
anim health market attract
first anim health typic lower risk higher predict earli
develop anim health typic far fewer clinic studi
requir fewer subject demonstr product safeti efficaci henc develop
time relat expens significantli less human pharmaceut
wherea develop human pharmaceut start anim studi clinic
program anim health end anim test addit opportun
leverag develop across multipl speci well applic innov
across pet care livestock
pleas see import disclosur inform page report
chart drug vs anim point comparison
consolid spin play signific role
reshap industri nonetheless anim
remain fairli fragment outsid largest four
larg pharma struggl growth seek creat valu investor
particip execut asset swap gain critic mass leadership certain
product segment exampl boehring ingelheim bi acquisit
sanofi merial anim health divis exchang sanofi took ownership bi
consum healthcar asset turn transact result divestitur certain
asset anim health compani address competitive/ftc regulatori concern
 elanco acquisit certain bi/vetmedica portfolio
spin-off zoeti larger anim health busi
mainli exist subsidiari major pharmaceut compani sinc separ
zoeti elanco anim health divis lilli spun march
howev remain signific anim health busi still oper
merck boehring ingelheim bayer corpor umbrella subsequ bayer anim
health agre acquir elanco august new combin
elanco bayer anim health expect creat second-largest compani
anim health industri assum merger receiv regulatori clearanc
consumm time-frame smaller scale spun
anim health busi merg vet first choic late form
focus practic manag softwar prescript manag
pleas see import disclosur inform page report
chart impend acquisit bayer anim health elanco creat
despit activ top leagu tabl anim health remain fragment
industri presenc small larg player compet term qualiti
price span wide rang segment includ focu companion
anim livestock diagnostic/servic data analyt feed etc unlik
zoeti would abl acquir signific therapeut focus anim health
compani given due anti-trust concern still appear mani ancillari
busi within anim health zoeti could continu bolt-on come year
pleas see import disclosur inform page report
anim healthcar product
zoeti growth outlook long-term secular trend drive compani two
main busi livestock companion anim segment benefit global
popul growth rise standard live
chart macro dynam shape futur anim
anim health product import maintain livestock health critic
current base billion peopl global popul expect increas
billion year accord unit nation base project
demand anim protein product dairi forecast vetnosi doubl
next year near term vetnosi indic protein demand
could increas yet still high loss livestock
mortal due diseas despit underli demand grow headwind
face human abil increas livestock product includ
arabl land alreadi degrad water shortages/drought global climat chang
increas competit cultiv land urban growth use
crop energi product
pleas see import disclosur inform page report
